ResMed Stock - Morgan Stanley downgrade weighs on shares
18.06.2026 - 19:39:11 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 17:30 UTC. Details in the imprint.
ResMed Inc. (US7611521078) faces fresh scrutiny from Wall Street after a rating cut by Morgan Stanley. The US investment bank downgraded the stock and reduced its price target, according to a recent analyst report summary.
All news and analysis on ResMed stock
Further updates, filings and headlines on ResMed stock are bundled in our dedicated topic area for this ISIN.
Morgan Stanley turns more cautious
According to the analyst note summarized by Yahoo Finance, Morgan Stanley cut its rating on ResMed from Overweight to Equal Weight and lowered its price target from $286 to $230. The bank cited limited room for near-term margin expansion and conservative earnings expectations.
The downgrade triggered a noticeable reaction in the market. ResMed shares were reported down around 4.5% intraday, before closing 3.9% lower at $186.34 in the referenced session. That left the stock roughly 23.7% below its level at the start of the year.
How the broader analyst view looks
Morgan Stanley’s move slots into an already mixed analyst backdrop for ResMed. Several firms had previously highlighted strong long-term demand for sleep and respiratory care, but also pointed to cost pressures and currency headwinds in recent quarters.
Consensus data from market platforms show ResMed still trading well below its 52-week high around $293.73 reached in August 2025, while remaining a large-cap name in global medical technology benchmarks. Net-net, the stock’s valuation debate now centers more on margins than on top-line growth.
The product behind the stock
ResMed generates most of its revenue with devices and software for treating sleep-disordered breathing and other chronic respiratory diseases, notably its AirSense line of CPAP machines and cloud-connected masks. The company also offers digital platforms that help clinics and patients monitor therapy adherence.
Where the stock trades today
ResMed shares (US7611521078) trade on the New York Stock Exchange under the ticker RMD at about $186 per share as of 06/18/2026, 17:00 UTC, with prices quoted in USD.
Key facts on ResMed stock
- Company: ResMed Inc.
- ISIN: US7611521078
- WKN: 895214
- Ticker: RMD
- Venue: NYSE
- Price (as of 06/18/2026, 17:00 UTC): 186.00 USD
- Market cap: 38,400,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care Equipment
- Index membership: S&P 500
- Next earnings date: 08/08/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
